Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALIFE2 study of low molecular weight heparin in recurrent miscarriage with inherited thrombophilia
NL-OMON43583Phase 3Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of low molecular weight heparin calcium in recurrent miscarriage (RPL) and Congenital Thrombophilia (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Live birth. Started Jan 2013; status: recruiting.
02
Drugs
low molecular weight heparin calcium
03
Conditions
recurrent miscarriage (RPL)Congenital Thrombophilia
Beyond the preview
Go deeper on NL-OMON43583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43583.